Business Wire

Omada Enables Advanced Governance Controls in Microsoft Azure Active Directory Premium

Del

Omada, the market-leading provider of solutions for advanced identity management and access governance, today announces a strategic alliance with Microsoft. The alliance is an expansion of the long-term relationship between the two companies. At the center of the solution is the seamless integration of Omada’s Identity governance platform with Microsoft Azure Active Directory Premium. Built on Azure, to govern access across hybrid environments. The solution provides customers with advanced access governance controls across all enterprise systems - on-premise and in the cloud.

The integration offers comprehensive governance features, allowing modern enterprises to ensure security, compliance and efficiency. With a 360-degree view of all access rights for all users, enterprises have the full overview and control of employees, contractors, partners, and their access, across hybrid environments.

Alex Simons, Director, Product Management, Microsoft Identity Division at Microsoft Corp. says,

“Our expanded integration with Omada is an important step in our journey to cover all dimensions of identity-driven security. Omada’s platform is built on Microsoft technology and is the perfect fit for Azure Active Directory Premium. The two solutions combined give customers a future-proof, and easy-to-use, identity management and access governance solution across on-premise and cloud.”

Creating measurable business value

Omada’s solution provides features such as user-friendly self-service access request portal, automation of access certification, and automation of the access review processes together with automated audit and compliance reporting.

“Since Omada was founded almost two decades ago, one of the key insights from our customer and partner engagements that has especially stood out has been: we help them do more with identity and create measurable business value,” says Morten Boel Sigurdsson, CEO and founder of Omada. “We are thrilled about announcing this strategic alliance between Microsoft and Omada, which takes our relationship to a new level and enables us to deliver even more value to our customers.”

Covering security, compliance and efficiency needs

The Omada Identity Platform is acknowledged for its strong identity governance capabilities by customers, partners, and leading analysts. When combined with the secure access and risk-based identity protection of Microsoft Azure Active Directory Premium, the solution enables customers to focus on their business by fully covering some of their most demanding security, compliance, and efficiency needs.

The strategic alliance enables organizations to enhance Microsoft’s access management and identity protection services with Omada’s identity governance and administration platform, built on Microsoft technologies. This means, that customers can use their already existing Microsoft expertise in the organization.

Do more with identity

At Omada, we are focused on using identity to create measurable business value –from IT and HR to Marketing and Sales. Identity, managed the Omada way, simultaneously improves security, efficiency, cost control, and regulatory compliance throughout any organization.

And, it can do even more. Identity can accelerate digital transformations, smooth M&A integration, and enable deeper relationships with suppliers and customers. Few technologies have the potential to impact so much. Belief in this essential role of identity unites our organization, fuels our innovation, and strengthens our collaboration with partners.

We’ve pioneered many of the best practices in use today, and are passionate about taking identity management even further. We are committed to using identity to create business value.

About Omada

Established in 2000, Omada has operations in North America and Europe, delivering solutions directly and via a network of skilled partners and system integrators.

Omada’s Identity Platform is recognized by Gartner in the ‘Critical Capabilities report for IGA’, where Omada received the 3rd highest scores in two out of four use cases.

Omada is a Microsoft Gold Certified Partner and three times global Microsoft Award winner of the Microsoft Identity & Secure Access Award, recognized for providing advanced identity and access governance scenarios utilizing the Microsoft stack. The Omada Identity Platform utilizes Microsoft technologies to provide enterprise-ready identity solutions across heterogeneous IT platforms, supporting hybrid scenarios. Omada’s certified solution is based on well proven components in the Microsoft technology stack like Windows Server, the .NET framework, SQL Server and BI services for enhanced analytics experiences.

Omada - DO MORE WITH IDENTITY

www.omada.net | info@omada.net

Contact information

Omada
Anne Dorthe H. Gyldenkærne, Vice President Global Marketing & Communication
T: +45 7025 0069
M: +45 2018 1881
e-mail: adg@omada.net
www.omada.net

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AURAK Gains SACSCOC Accreditation15.12.2018 10:49Pressemelding

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha